Will GenScript’s Industrial Synthetic Biology segment report an operating profit in the first half of 2023?

Started Dec 08, 2022 08:00PM UTC
Closed Jul 01, 2023 04:00AM UTC

GenScript is a biotechnology company that uses gene synthesis technology to produce enzymes needed for ethanol production through its industrial synthetic biology subsidiary, Bestzyme. In 2021, GenScript reported an operating profit for the Industrial Synthetic Biology segment of $0.01 million (i.e., $10,000) (2021 Annual Results, pg. 18) after reporting losses in 2019 and 2020 (2020 Annual Results, pg. 15). Operating profit grew to $0.4 million in the first half of 2022 (2022 Interim Results, pg. 19).  
This question will resolve as “Yes” if GenScript reports an operating profit (i.e., they report a non-zero and positive "Adjusted segment operating profit/loss") for their Industrial Synthetic Biology segment for the 1st Half of 2023, which ends 30 June 2023. We expect the 2023 1H operating profit to be recorded in the 2023 Interim Results Report, which is released in the second half of 2023. Past interim and annual report presentations are available here.
Resolution Notes

Genzyme reported a $0.3 million operating profit for their Industrial Synthetic Biology segment in their 2023 Interim Report.

Possible Answer Correct? Final Crowd Forecast
Yes 95.01%
No 4.99%

Crowd Forecast Profile

Participation Level
Number of Forecasters 53
Average for questions older than 6 months: 58
Number of Forecasts 260
Average for questions older than 6 months: 190
Participants in this question vs. all forecasters better than average

Most Accurate

Relative Brier Score


Consensus Trend

Tip: Mention someone by typing @username